Jonathan Beatson-Hird

Jonathan has 26 years experience in both Emerging Companies and Emerging Markets. His core expertise is in equities, covering research, sales and corporate finance. He spent 8 years in New York as a Managing Director of Barings and Deutsche Bank. In 2000, Jonathan was a founding partner of New Boathouse Capital, a private equity firm and in 2005 he helped build the team at Ambrian Partners. He ran an EIS Fund investing in private equity in the oncology sector with Professor Tony Atkinson. During his 28 years in finance, he raised billions of pounds for well over 200 companies in the biotech, infrastructure, mining and renewable energy sectors.

Jonathan co-founded Sarum Partners. His experience in sector specialisation has led him to believe in the strength and effectiveness of focusing in a single part of the market. His work with Prof Tony Atkinson over the last 5 years has enforced his belief that we are seeing a once in a lifetime opportunity of investing in the oncology sector due to the revolution in our understanding of the dynamics of cancer and how we may now best treat it. He has assembled a team which has a diverse range of skill sets and disciplines which he believes will enable the Sarum Investment SICAV Plc to pick the best of breed and mitigate some of the risks that are inherent in the biotech and healthcare sector.

Drug & Diagnostic Development Expertise

Dr Michele Hill-Perkins (London)

Michele has an MSc in Radiation Biology and a PhD in Biochemistry. She has worked as the Senior Business Manager at Cancer Research Ventures Ltd and launched first start-up company for the Marie Curie Institute. She has worked for British Biotechnology plc as Senior Research Scientist and Head of Laboratory, and the Institute of Virology Oxford where she developed a range of patent protected novel expression systems that were successfully out-licensed to Pharmingen for widespread commercial and academic use. She is currently Director of technology transfer at the London teaching hospitals.

Dr Andy Shuttleworth

Andy spent 20 years at the Porton Down research establishments involved in both fundamental research in microbiology and immunology, and the application of that research to pressing problems of the day. He was largely responsible for the UK’s first practical biological agent detection system, fielded during the Gulf War in 1991. He was invited to take part in United Nations inspections in Iraq and other inspections of biological facilities in Russia, the UK and the US throughout the 1990s. Throughout his career Andy has specialized in identifying and exploiting novel applications for established and cutting edge science, frequently bridging them into unrelated fields of activity. Therefore, he is well experienced in bringing different technologies together from disparate sectors and sources and has a proven and successful track record. His experience is invaluable in diagnostics and medical devices.

Andy is currently providing scientific and technical advice to a world-beating microbial fuel cell project involved in waste water remediation and micro-scale power generation.

Oncology Entrepreneurs

Sir Roger Jones (Cardiff)

Sir Roger is a specialist in the economics of pharmaceutical development. He is a former Chairman of the Welsh Development Agency and a Governor of the BBC and worked for Wellcome Foundation Ltd setting up commercial operations in Africa, the Middle and Far East and the Eastern Bloc. In 1986 he established Penn Pharmaceuticals Ltd which has been a leading provider of fully integrated and cost effective pharma development outsourcing services. He also founded Lansdale Pharmacies, Alzeim and Zoobiotics. He was awarded an OBE in 1996 for services to the Pharmaceutical Industry and Knighted in the 2005 New Years Honours.

Dr George Cautherley OBE (Hong Kong)

Dr Cautherley is a 5th Generation Hong Kong resident where he has spent all his professional life. He holds a number of senior executive and advisory roles in the medical products industry. His principle business activity has been in marketing and distributing pharmaceuticals and medical products in Hong Kong and in Mainland China through the company he founded, HCD Holdings. HCD Holdings is a diagnostic business that was sold for €990m in 2009. Dr Cautherley has manufacturing facilities in China and is on the board of the main Hong Kong political think tank. He was awarded an Honorary Doctorate of Business Administration by Edinburgh Napier University and was awarded an OBE in Her Majesty the Queen’s 2008 Birthday Honours for services to public policy development in Hong Kong

Professor Gordon McVie (Milan)

Professor McVie is Senior Consultant at the European Institute of Oncology, (IEO), and Director of Cancer Intelligence, Bristol. He is past CEO of Cancer Research Campaign, now CRUK, and while there, stimulated Phase 1 studies of over 50 novel compounds from Academia, while through Cancer Research Campaign Technology, setting up ten biotechnology companies based on the charity’s Intellectual Property. His contributions to cancer care are in the optimisation of locoregional chemotherapy, and new drug development, particularly in cancers of the breast, ovary, lung and brain.

Professor McVie has over 300 publications and has served as President of EORTC, and on several committees in the USA and Europe including The American Association for Cancer Research and the American Society for Clinical Oncology. He has recently initiated ecancermedicalscience, an open access free cancer journal founded by ECCO and the IEO.

City Expertise and Fund Raising

Guillermo Serrano

25 years experience in financial markets both in Europe and in the Americas. His early years in the Spanish equities market with Hoarge Govet and Goldman Sachs served as a springboard to a number of Emerging Markets roles where he became a no.1 ranked analyst in the Institutional Investor survey with Barings. He then later moved to Santander where his team maintained investor rankings and then onto Dresdner Kleinwort Benson and BBVA.

Since 2005, Guillermo has developed an expertise in emerging technologies, particularly in the clean tech sector at Nomura Code Securities. Within the space, he has been particularly involved in companies in the waste-to-energy sector and material sciences, together with a generalist approach to the healthcare technology sector.

In the London market, Guillermo has been instrumental in the success of numerous transactions such as Ceramic Fuel Cells, TMO Renewables, ITM Power, Ilika, MDx Health, Biotie, Vernalis, Futura Medical, Carmat, Silence Therapeutics and Intercell.

Jonny Laughton

Jonny’s experience is in building high growth technology businesses both within the UK, Europe and Emerging markets. He helped found Star in 1995, which grew to £50 Million of recurring revenues before being sold, Jonny had overall responsibility for Sales & Commercial aspects of the business.

He then helped found Messagelabs and was Director of Emerging Markets, taking the business into new territories. Messagelabs grew to become the 3rd largest Messaging Security business globally with 700 people worldwide and revenues of approx $150 Million recurring when it was bought in November 2008 for $695 million by Symantec Corporation.

Jonny is also a member of Sarum Capital LLP and Investment Committee Member of Sarum Investment SICAV plc.

Oliver de Giorgio-Miller

Oliver has over 20 years experience in the commercial advancement and management of life science companies. He held senior commercial positions in global biopharmaceutical and medical device organisations, Schering AG, Hoffman la Roche and Intavent-Orthofix, before he became CEO of a number of start-up or emerging companies, including Photo Therapeutics Group, a company of Cancer Research UK. Since 2002 Oliver has been working in the City as a Consultant to UK Corporate Finance and Stockbroking firms with clients in the life sciences sector. He is actively involved in a wide range of corporate finance transactions including fundraising via private placings, IPOs, secondary issues, mergers and acquisitions, predominantly in the healthcare sector, but also in the renewable energy sector. He has extensive contacts with institutional investors.

Oliver is also a member of Sarum Capital LLP and Investment Committee Member and Director of Sarum Investment SICAV plc.

Patient Interface

Dr Nick Plowman (London)

Dr Plowman is the Senior Clinical oncologist to St Bartholomew’s Hospital and The Hospital for Sick Children Great Ormond St with visiting duties to St Mark’s Hospital for diseases of the rectum and colon and Moorfields Eye Hospital. He has been Head of Department at St Bartholomew’s from 1889-1997 and from 2000 to the present time. Dr Plowman’s special interests are directed towards improving cure rates in cancer, whilst reducing the side effects of therapy. He is an expert on both radiation therapy and chemotherapy. He has helped develop a number of oncology related instruments including the Cyber Knife.

Dr Karol Sikora, MD, PhD (London)

Karol Sikora is Medical Director of CancerPartnersUK which is creating the largest independent UK cancer network. He was Professor and Chairman of the Department of Cancer Medicine at Imperial College School of Medicine and is still honorary Consultant Oncologist at Hammersmith Hospital, London. He is Dean and Professor of Medicine at Britain’s first independent Medical School at the University of Buckingham and a fellow of Corpus Christi College, Cambridge He has published over 300 papers and written or edited 20 books including Treatment of Cancer – the standard British postgraduate textbook now in its fifth edition and most recently The Economics of Cancer Care. He is on the editorial board of several journals and is the founding editor of Gene Therapy and Cancer Strategy. He was a member of the UK Health Department’s Expert Advisory Group on Cancer (the Calman-Hine Committee), the Committee on Safety of Medicines.

Dr Teresa Zimmers (Miami)

Dr. Zimmers received her BS in Biology from the Massachusetts Institute of Technology and her Ph.D. in Molecular Biology and Genetics from the Johns Hopkins University School of Medicine. She has published expertise in cancer outcomes, chemoprevention, cancer cachexia and the molecular pathways regulating organ size, including liver regeneration, intestinal homeostasis and skeletal muscle growth regulation. She has been funded for cancer research through the United States Department of Defense, the National Cancer Institute, the American Cancer Society and the United States National Institutes of Health.  Teresa is currently the Associate Professor of Cancer Biology at the Kimmel Cancer Centre, Thomas Jefferson University, Philadelphia – working on the Gastrointestinal Cancer Program.